Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Prologis Inc (PLD) Price & Performance

Amylx Pharmaceuticals IncTrade
Prologis IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Prologis Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Prologis Inc trades at $138.59 (market cap $133.20B). The key difference: Prologis Inc is far larger — about 52.6× Amylx Pharmaceuticals Inc's market cap, and Prologis Inc pays a 3.05% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXPLD
Market Cap
$2.53B$133.20B
Sector
HealthReal Estate
52-Week High
$24.19$149.96
52-Week Low
$7.82$104.81
Enterprise Value
$2.28B$167.94B
Dividend Yield
3.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Prologis Inc

Prologis (PLD) trades at $140.16, up 0.73% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and consistent earnings beats. Recent news highlights the acquisition of SEGRO for up to $19.2 billion, expanding its European footprint, alongside a common stock offering to fund growth. Cash flow trends show variability, with 2025 net cash flow negative at -$172.94 million but projected to rebound in 2026.

The outlook is positive due to robust earnings growth, strategic acquisitions, and a 57% analyst buy rating with a $159.22 price target. Risks include high debt levels, with debt-to-asset ratio rising to 37.2 in 2025, and integration challenges from the SEGRO deal. Investors should weigh strong profitability against leverage and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Prologis Inc

Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.

Read more on PLD